United Healthは,医療費の増加と規制問題によるQ22025における収益の見積りについて,強い収益の増加にもかかわらず,全年度の指導を低下させた. UnitedHealth missed earnings estimates in Q2 2025 due to rising medical costs and regulatory issues, lowering full-year guidance despite strong revenue growth.

ユナイテッドヘルスグループは,推定額を欠いた2025年第2四半期に株当たり4.08ドルの利益を報告し,売上高は前年比12.9%増加して11162億米ドルとなった. UnitedHealth Group reported second-quarter 2025 earnings of $4.08 per share, missing estimates, with revenue up 12.9% year-over-year to $111.62 billion. 同社は,全年度のEPSガイドラインを160ドルに改め,医療費,特に医薬品の有効性及び規制の課題について,高額の医療費を示唆している. The company revised its full-year EPS guidance to $16.00, citing higher medical costs, especially in Medicare Advantage, and regulatory challenges. 総勢で"適度な買い"と358.95ドルの目標価格が認められたにもかかわらず,医療損失率の上昇と市場前4%の減少を懸念して株価は下落した. Despite a consensus "Moderate Buy" rating and a $358.95 target price, the stock dropped amid concerns over rising medical loss ratios and a 4% pre-market decline. 会社は2.6%の配当率を維持し,4つのセグメントを通じて運営され,強力な機関所有権を持っています. The company maintains a 2.6% dividend yield, operates through four segments, and has strong institutional ownership, though some firms reduced stakes while others increased positions.